Summation
- Ensuring that patients receive an effective drug early in treatment is a cornerstone of this program, and we are excited to offer Mind.
- Liviniti, a national PBM leader in transparency and prescription drug savings, announces a new collaboration with Mindera Health to improve management of moderate-to-severe psoriasis patients.
- Successful patient responses to currently available biologic treatments are approximately 52%, leading to trial-and-error and increased costs to get patients on the most effective treatment.
Liviniti, a national PBM leader in transparency and prescription drug savings, announces a new collaboration with Mindera Health to improve management of moderate-to-severe psoriasis patients. The program utilizes Mind.Px™, a dermal biomarker patch, to improve clinical outcomes while reducing biologic drug costs for self-funded employers.
“Inflammatory conditions are a major cost trend driver in the specialty pharmacy space,” says LeAnn Boyd, Liviniti CEO. “Leveraging pharmacogenomics through our collaboration with Mindera Health supports improved treatment outcomes for patients with psoriasis and reduced plan costs for expensive biologics. Ensuring that patients receive an effective drug early in treatment is a cornerstone of this program, and we are excited to offer Mind.Px to our clients and their members.”
Mind.Px predicts the appropriate biologic drug class for an individual patient prior to treatment. It allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians, with >92% positive predictive values. By matching the patient to the right drug class before treatment begins, potential cost savings can be substantial.
“We are delighted to partner with a pharmacy benefit manager like Liviniti to introduce precision medicine to psoriasis patients,” says Ron Rocca, President and CEO of Mindera Health. “We share core values to bring innovation to significant markets to decrease drug costs while improving patient outcomes.”
In the United States, psoriasis affects more than 3% of the population, leading to healthcare costs of more than $110B annually. Specialty drug spend for psoriasis is escalating, and biologics are often identified by payers as one of their top drug expenditures each year. Successful patient responses to currently available biologic treatments are approximately 52%, leading to trial-and-error and increased costs to get patients on the most effective treatment
